Ocaperidone is an effective antipsychotic agent acting as a potent 5-HT2 and dopamine D2 antagonist and a 5-HT1A agonist with Kis of 0.14 nM 0.46 nM 0.75 nM 1.6 nM and 5.4 nM for 5-HT2 a1-adrenergic receptor dopamine D2 histamine H1 and a2-adrenergic receptor respectively and a pEC50 and pKi of 7.60 and 8.08 for h5-HT1A.

For R&D use onlynot for drug household or other uses.

Ocaperidone (also R 79598) is a benzisoxazole antipsychotic. It was initially developed by Janssen later licensed to French laboratory Neuro3D and then acquired in 2007 by German company Evotec. Its testing was abandoned after phase II trials as of 22 February 2010.